Radiotherapy Dose Optimization in diffuse large B Cell Lymphoma
- Conditions
- Health Condition 1: null- Histologically proven cases of Diffuse large B cell Non hodgkins lymphoma
- Registration Number
- CTRI/2016/11/007485
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1.Histological diagnosis of NHL-Diffuse laarge B cell lymphoma
2.Eligible for RT after R-CHOP chemotherapy regimen
3. ECOG 0-3
4. 18-59 YEARS
5. STAGE I-IV
6. Patient should receive atleast 4 cycles of R-CHOP chemotherapy
7. Patients with extranodal disease except one mentioned in the exclusion criteria
8. Able to understand and willing to provide informed consent for participation in the trial.
1. HIV positive status
2.Relapse or progression of disease during chemotherapy
3. Prior history of chemotherapy
4. Systemic lymphomas with cns involvement
5. Primary extranodal testicular lymphomas
6. Primary extranodal CNS Lymphomas
7. Primary extranodal Stomach DLBCL
8. primary extranodal intestinal lymphoma
9. patient with >3 extranodal sites
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Event Free SurvivalTimepoint: 2 years
- Secondary Outcome Measures
Name Time Method ate ToxicityTimepoint: 2 years;Acute toxicityTimepoint: during radiation and upto 6 weeks after completion of RT;Local control ratesTimepoint: 2 years;Overall Response RateTimepoint: 3 months;Overall SurvivalTimepoint: 2 years;Quality Of Life scoresTimepoint: 2 years